alendronate has been researched along with Diabetes Mellitus in 8 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to perform a meta-analysis of the effects of alendronate combined with atorvastatin compared with alendronate alone in the treatment of osteoporosis in diabetes mellitus." | 9.22 | Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus. ( Shu, L; Tang, X; Xiong, Z; Yi, P; Zhang, C, 2022) |
| "To explore the anti-osteoporosis and anti-diabetes effects and potential underlying mechanisms of treatment with metformin and alendronate in diabetes mellitus mice." | 8.12 | The effects of metformin and alendronate in attenuating bone loss and improving glucose metabolism in diabetes mellitus mice. ( Chen, H; Guan, Z; Han, G; Jin, X; Liu, S; Tao, K; Xuan, Y; Zhou, Q, 2022) |
| "A 10% increased risk of acute myocardial infarction was found in users of other bisphosphonates as compared to alendronate users within CPRD." | 5.22 | Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database. ( Abrahamsen, B; Arden, N; Calderon-Larranaga, S; Cooper, C; Hawley, S; Javaid, MK; Judge, A; Khalid, S; Prieto-Alhambra, D; Sami, A; Van Staa, TP, 2022) |
| " The aim of this study was to perform a meta-analysis of the effects of alendronate combined with atorvastatin compared with alendronate alone in the treatment of osteoporosis in diabetes mellitus." | 5.22 | Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus. ( Shu, L; Tang, X; Xiong, Z; Yi, P; Zhang, C, 2022) |
| "To explore the anti-osteoporosis and anti-diabetes effects and potential underlying mechanisms of treatment with metformin and alendronate in diabetes mellitus mice." | 4.12 | The effects of metformin and alendronate in attenuating bone loss and improving glucose metabolism in diabetes mellitus mice. ( Chen, H; Guan, Z; Han, G; Jin, X; Liu, S; Tao, K; Xuan, Y; Zhou, Q, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, Q | 1 |
| Guan, Z | 2 |
| Liu, S | 1 |
| Xuan, Y | 1 |
| Han, G | 1 |
| Chen, H | 1 |
| Jin, X | 1 |
| Tao, K | 1 |
| Khalid, S | 1 |
| Calderon-Larranaga, S | 1 |
| Sami, A | 1 |
| Hawley, S | 1 |
| Judge, A | 1 |
| Arden, N | 1 |
| Van Staa, TP | 1 |
| Cooper, C | 1 |
| Abrahamsen, B | 1 |
| Javaid, MK | 1 |
| Prieto-Alhambra, D | 1 |
| Xiong, Z | 1 |
| Yi, P | 1 |
| Tang, X | 1 |
| Shu, L | 1 |
| Zhang, C | 1 |
| Généreux, P | 1 |
| Chernin, G | 1 |
| Assali, AR | 1 |
| Peruga, JZ | 1 |
| Robinson, SD | 1 |
| Schampaert, E | 1 |
| Bagur, R | 1 |
| Mansour, S | 1 |
| Rodés-Cabau, J | 1 |
| McEntegart, M | 1 |
| Gerber, R | 1 |
| L'Allier, P | 1 |
| de Silva, R | 1 |
| Daneault, B | 1 |
| Aggarwal, SK | 1 |
| Džavík, V | 1 |
| Ozan, MO | 1 |
| Ben-Yehuda, O | 1 |
| Maehara, A | 1 |
| Stone, GW | 1 |
| Jonas, M | 1 |
| Di Fede, O | 1 |
| Fusco, V | 1 |
| Matranga, D | 1 |
| Solazzo, L | 1 |
| Gabriele, M | 1 |
| Gaeta, GM | 1 |
| Favia, G | 1 |
| Sprini, D | 1 |
| Peluso, F | 1 |
| Colella, G | 1 |
| Vescovi, P | 1 |
| Campisi, G | 1 |
| Brandt, NJ | 1 |
| Stefanacci, RG | 1 |
| Tanimoto, K | 1 |
| Okubo, Y | 1 |
| Harada, C | 1 |
| Saito, H | 1 |
| Sata, A | 1 |
| Nishikawa, A | 1 |
| Ohwada, R | 1 |
| Tsuiki, M | 1 |
| Yamamoto, M | 1 |
| Hashimoto, E | 1 |
| Sato, K | 1 |
| Takano, K | 1 |
| Heckbert, SR | 1 |
| Li, G | 1 |
| Cummings, SR | 1 |
| Smith, NL | 1 |
| Psaty, BM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Biorest Liposomal Alendronate Administration for Diabetic Patients Undergoing Drug-Eluting Stent Percutaneous Coronary Intervention[NCT02645799] | Phase 2 | 270 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for alendronate and Diabetes Mellitus
| Article | Year |
|---|---|
Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Databases, Factual; Diabetes Mellitus | 2022 |
Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus.
Topics: Alendronate; Alkaline Phosphatase; Atorvastatin; Bone Density; Bone Density Conservation Agents; Dia | 2022 |
1 trial available for alendronate and Diabetes Mellitus
| Article | Year |
|---|---|
Double-blind, placebo-controlled evaluation of biorest liposomal alendronate in diabetic patients undergoing PCI: The BLADE-PCI trial.
Topics: Alendronate; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus; Drug-Eluting Stents; | 2022 |
5 other studies available for alendronate and Diabetes Mellitus
| Article | Year |
|---|---|
The effects of metformin and alendronate in attenuating bone loss and improving glucose metabolism in diabetes mellitus mice.
Topics: Alendronate; Animals; Blood Glucose; Bone Demineralization, Pathologic; Bone Density; Bone Density C | 2022 |
Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: a retrospective multi-hospital-based study of 87 Italian cases.
Topics: Administration, Oral; Adrenal Cortex Hormones; Age Factors; Aged; Aged, 80 and over; Alendronate; Bi | 2013 |
Discontinuation of unnecessary medications in older adults.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Ulcer Agents; Antihypertensive Agents; Assisted Living Fa | 2011 |
Latent hypoparathyroidism in an osteoporotic patient with multiple endocrinopathies and secondary hemochromatosis due to multiple blood transfusions, unmasked by alendronate and glucocorticoid at adrenal crisis.
Topics: Adrenal Glands; Adult; Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcium; Diab | 2008 |
Use of alendronate and risk of incident atrial fibrillation in women.
Topics: Aged; Aged, 80 and over; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Case-Co | 2008 |